Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 14Gastrointestinal 4Thoracic 2Sarcoma 2Genitourinary 2Breast 2Myeloid 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Melanoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Lung Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Thyroid Neoplasms 1Soft Tissue Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1

Interventions

Peripheral Blood Stem Cell Transplantation 6Cyclophosphamide 6fludarabine phosphate 5Nivolumab 5Mycophenolic Acid 5Carboplatin 5Whole-Body Irradiation 4Radiotherapy 4Filgrastim 4Cyclosporine 4Gemcitabine 3Cisplatin 3Busulfan 3Antilymphocyte Serum 3cabozantinib 2cabazitaxel 2Voriconazole 2Thiotepa 2Therapeutics 2Standard of Care 2Sirolimus 2Polymerase Chain Reaction 2Mitomycin 2Methylprednisolone 2Methotrexate 2Melphalan 2Itraconazole 2Immunoglobulin G 2Goserelin 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Cetuximab × Genitourinary × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡